BLAIV (INFUSION)INJECTABLEPriority Review
Approved
Apr 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
MYOZYME (alglucosidase alfa) by Sanofi is (acid maltase deficiency, glycogen storage disease type ii, gsd ii, glycogenosis type ii) is an inherited disorder of glycogen metabolism caused by the absence or marked deficiency of the lysosomal enzyme gaa. Approved for pompe disease, acid maltase deficiency. First approved in 2006.
Drug data last refreshed 18h ago
Mechanism of Action
(acid maltase deficiency, glycogen storage disease type II, GSD II, glycogenosis type II) is an inherited disorder of glycogen metabolism caused by the absence or marked deficiency of the lysosomal enzyme GAA. Alglucosidase alfa provides an exogenous source of GAA. Binding to mannose-6-phosphate…
Indications (2)
Worked on MYOZYME at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.